Ryoncil® Continues Successful First Year Launch with Net Sales of US$30.3M in March Quarter
MWN-AI** Summary
Mesoblast Limited (Nasdaq: MESO; ASX: MSB) has reported strong financial performance related to the launch of Ryoncil® (remestemcel-L-rknd), with net sales reaching an impressive US$30.3 million for the quarter ending March 31, 2026. This robust figure reflects a significant rebound in sales during February and March, effectively countering the seasonal dip typically seen in January. Since its launch, Ryoncil® generated nearly US$100 million in revenues, bolstering Mesoblast's balance sheet and providing financial backing for ongoing label expansions and late-stage projects.
Ryoncil® is noteworthy as the first FDA-approved mesenchymal stromal cell (MSC) therapy for any indication, specifically targeting children under 12 suffering from steroid-refractory acute graft-versus-host disease (SR-aGvHD). Dr. Silviu Itescu, CEO of Mesoblast, praised the product's performance and announced plans to present a growth strategy and insight into the company's product pipeline at an upcoming R&D event. This event is scheduled for April 8, 2026, in New York City, and will feature discussions from senior leadership and industry experts.
With a strong global presence, Mesoblast is committed to developing allogeneic cell therapies to address severe inflammatory conditions. The company also holds a robust intellectual property portfolio, with over 1,000 patents or applications offering extensive commercial protection through at least 2044. In addition to Ryoncil®, other initiatives include therapies for adult patients and various inflammatory diseases linked to their proprietary cell therapy technology.
For more information about Ryoncil® and other Mesoblast offerings, interested parties can visit the company's website or tune in to the live webcast of the R&D Day.
MWN-AI** Analysis
Mesoblast Limited (Nasdaq:MESO; ASX:MSB) has reported remarkable net sales of Ryoncil® (remestemcel-L-rknd) reaching US$30.3 million for the March quarter. The impressive performance following the seasonal dip in January can be attributed to strong sales growth in February and March. Overall, Ryoncil® revenue is close to the US$100 million mark in its first year, substantially bolstering Mesoblast’s financial position.
Given the unique status of Ryoncil® as the first FDA-approved mesenchymal stromal cell therapy for pediatric patients with steroid-refractory acute graft-versus-host disease (SR-aGvHD), the product holds significant market potential. Mesoblast’s strong sales figures and innovative positioning in the market suggest continued demand, particularly as the company optimizes its marketing strategy and navigates regulatory pathways for label extensions.
Investors should closely monitor developments from Mesoblast, particularly the upcoming R&D Day scheduled for April 8, 2026, where key growth strategies and insights into their late-stage product pipeline will be shared. This can provide valuable information regarding the company’s future direction and potential catalysts that may drive stock value.
Additionally, Mesoblast is aggressively pursuing expansion opportunities in Europe, Japan, and China, which can lead to diversified revenue streams and risk mitigation. Their robust global intellectual property portfolio ensures competitive protection and likely supports market exclusivity until at least 2044.
In conclusion, Mesoblast presents a compelling opportunity for investors, given the strong initial sales of Ryoncil® and the potential for future growth. However, it's essential for prospective investors to remain cautious, considering market risks and uncertainties associated with clinical developments and regulatory approvals. A careful assessment of these factors can guide informed investment decisions in Mesoblast Ltd.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Strong growth in February/March following January seasonality
Net revenue approaches US$100M since launch
NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced Ryoncil® (remestemcel-L-rknd) net sales were US$30.3 million for the quarter ended March 31, 2026.1 Strong sales in February and March offset holiday seasonality in January. Revenue generated during this first year of Ryoncil® launch approaches US$100 million.
Ryoncil® revenue strengthens Mesoblast's balance sheet and supports label extension and late-stage blockbuster programs. Ryoncil® is the first mesenchymal stromal cell (MSC) product approved by the U.S. Food and Drug Administration (FDA) for any indication and is the only FDA-approved product for children under age 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).2
“Revenue for Ryoncil® continues to be impressive,” said Mesoblast Chief Executive Dr. Silviu Itescu. “We will outline our growth strategy for Ryoncil® as well as our robust late-stage product pipeline at our inaugural R&D event this week.”
Mesoblast will host its inaugural R&D Day on Wednesday, April 8, 2026, in New York City. The event will be webcast live from 8:00am to 11:00am EST and will include presentations from Mesoblast’s senior leadership team and from key opinion leaders.
The webcast can be accessed via: https://webcast.openbriefing.com/msb-inv-2026/
A replay of the webcast will be available shortly after the conclusion of event on the Company’s website: www.mesoblast.com
About Mesoblast
Mesoblast (the Company) is a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The therapies from the Company’s proprietary mesenchymal lineage cell therapy technology platform respond to severe inflammation by releasing anti-inflammatory factors that counter and modulate multiple effector arms of the immune system, resulting in significant reduction of the damaging inflammatory process.
Mesoblast’s Ryoncil® (remestemcel-L-rknd) for the treatment of steroid-refractory acute graft versus host disease (SR-aGvHD) in pediatric patients 2 months and older is the first FDA-approved mesenchymal stromal cell (MSC) therapy. Please see the full Prescribing Information at www.ryoncil.com.
Mesoblast is committed to developing additional cell therapies for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Ryoncil® is being developed for additional inflammatory diseases including SR-aGvHD in adults and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for heart failure and chronic low back pain. The Company has established commercial partnerships in Japan, Europe and China.
About Mesoblast intellectual property: Mesoblast has a strong and extensive global intellectual property portfolio, with over 1,000 granted patents or patent applications covering mesenchymal stromal cell compositions of matter, methods of manufacturing and indications. These granted patents and patent applications provide commercial protection extending through to at least 2044 in all major markets.
About Mesoblast manufacturing: The Company’s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.
Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see www.mesoblast.com, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast
References / Footnotes
- The revenues included in this press release are based on management’s initial analysis of operations for the third quarter ended March 31, 2026, and are subject to completion of Mesoblast’s financial closing procedures and audit.
- Please see the full Prescribing Information at www.ryoncil.com
Forward-Looking Statements
This press release includes forward-looking statements that relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. We make such forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Forward-looking statements should not be read as a guarantee of future performance or results, and actual results may differ from the results anticipated in these forward-looking statements, and the differences may be material and adverse. Forward-looking statements include, but are not limited to, statements about: the initiation, timing, progress and results of Mesoblast’s preclinical and clinical studies, and Mesoblast’s research and development programs; Mesoblast’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; Mesoblast’s ability to advance its manufacturing capabilities; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities, if any; the commercialization of Mesoblast’s RYONCIL for pediatric SR-aGVHD and any other product candidates, if approved; regulatory or public perceptions and market acceptance surrounding the use of stem-cell based therapies; the potential for Mesoblast’s product candidates, if any are approved, to be withdrawn from the market due to patient adverse events or deaths; the potential benefits of strategic collaboration agreements and Mesoblast’s ability to enter into and maintain established strategic collaborations; Mesoblast’s ability to establish and maintain intellectual property on its product candidates and Mesoblast’s ability to successfully defend these in cases of alleged infringement; the scope of protection Mesoblast is able to establish and maintain for intellectual property rights covering its product candidates and technology; estimates of Mesoblast’s expenses, future revenues, capital requirements and its needs for additional financing; Mesoblast’s financial performance; developments relating to Mesoblast’s competitors and industry; and the pricing and reimbursement of Mesoblast’s product candidates, if approved. You should read this press release together with our risk factors, in our most recently filed reports with the SEC or on our website. Uncertainties and risks that may cause Mesoblast’s actual results, performance or achievements to be materially different from those which may be expressed or implied by such statements, and accordingly, you should not place undue reliance on these forward-looking statements. We do not undertake any obligations to publicly update or revise any forward-looking statements, whether as a result of new information, future developments or otherwise.
Release authorized by the Chief Executive.
For more information, please contact:
| Corporate Communications / Investors | |
| Paul Hughes | |
| T: +61 3 9639 6036 | |
| Media – Global | Media – Australia |
| Rubenstein | BlueDot Media |
| Caroline Nelson | Steve Dabkowski |
| T: +1 703 489 3037 | T: +61 419 880 486 |
| E:cnelson@rubenstein.com | E:steve@bluedot.net.au |
FAQ**
How does Mesoblast Limited MESO plan to sustain its strong revenue growth for Ryoncil® in the upcoming quarters, especially after the impressive February and March sales?
With Ryoncil® nearing US$100 million in net revenue since its launch, what strategies does Mesoblast Limited MESO have in place for further expanding its market presence in pediatric treatments?
Can you elaborate on the late-stage product pipeline that Mesoblast Limited MESO plans to highlight at the R&D Day, and how it relates to Ryoncil®'s success?
What protective measures does Mesoblast Limited MESO have in place to safeguard its extensive intellectual property portfolio related to its MSC therapies, especially in competitive markets?
**MWN-AI FAQ is based on asking OpenAI questions about Mesoblast Limited (NASDAQ: MESO).
NASDAQ: MESO
MESO Trading
2.2% G/L:
$15.995 Last:
26,757 Volume:
$16.11 Open:
